Login / Signup

Author Correction: Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.

Catherine J MummeryAnne Börjesson-HansonDaniel J BlackburnEverard G B VijverbergPeter Paul De DeynSimon DucharmeMichael JonssonAnja SchneiderJuha O RinneAlbert C LudolphRalf BodenschatzHolly KordasiewiczEric E SwayzeBethany FitzsimmonsLaurence MignonKatrina M MooreChris YunTiffany BaumannDan LiDaniel A NorrisRebecca CreanDanielle L GrahamEllen HuangElena RattiC Frank BennettCandice JungeRoger M Lane
Published in: Nature medicine (2023)
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • phase iii
  • open label
  • cognitive decline
  • phase ii
  • cancer therapy
  • randomized controlled trial
  • nucleic acid